A61K 39/00111
Hepatocyte growth factor receptor [hgfr or c-met]
Official title: {Hepatocyte growth factor receptor [HGFR or c-met]}
A61K39/00111 (Hepatocyte growth factor receptor [hgfr or c-met]) appears on 35 US grants and 57 published applications in this corpus.
Search patents in A61K- Granted patents
- 35
- Published applications
- 57
- Assignees
- 22
- Inventors
- 63
- Latest grant
- 10 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 3 |
| 2016 | 0 | 4 |
| 2017 | 1 | 4 |
| 2018 | 1 | 6 |
| 2019 | 4 | 6 |
| 2020 | 5 | 8 |
| 2021 | 2 | 5 |
| 2022 | 3 | 12 |
| 2023 | 9 | 2 |
| 2024 | 7 | 3 |
| 2025 | 2 | 3 |
By publication year.
Recent patents
- Compositions and methods for delivery of biomacromolecule agents10 Jun 2025US 12,324,843 B2The Regents of the University of Michigan
- Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination7 Jan 2025US 12,186,275 B2BioNTach Ceil & Gene Therapies GmbH and TRON—Translationaie Onkologie an der Universitaismedizin der Johannes Gutenberg-univer
- Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers22 Oct 2024US 12,121,572 B2Immatics Biotechnologies GmbH
- Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers24 Sep 2024US 12,097,248 B2Immatics Biotechnologies GmbH
- Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers3 Sep 2024US 12,076,380 B2Immatics Biotechnologies GmbH
- Compositions and methods for delivery of biomacromolecule agents25 Sep 2025US 2025/0295805 A1The Regents of the University of Michigan
- Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof5 Jun 2025US 2025/0177505 A1Korea University Research and Business Foundation
- Cancer vaccine comprising epitope of c-met and use thereof1 May 2025US 2025/0134975 A1Korea University Research and Business Foundation
- Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers12 Dec 2024US 2024/0408166 A1Immatics Biotechnologies GmbH
- Compositions and methods for delivery of biomacromolecule agents11 Apr 2024US 2024/0115679 A1The Regents of the University of Michigan
Most cited
By later US patents
- Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses34US 9,044,420 B2Immune Design Corp. · 2015
- Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers10US 10,064,926 B2Immatics Biotechnologies GmbH · 2018
- Target peptides for immunotherapy and diagnostics4US 9,561,266 B2The University of Birmingham · 2017
- Arenavirus particles as cancer vaccines3US 11,266,727 B2Hookipa Biotech GmbH · 2022
- Target peptides for colorectal cancer therapy and diagnostics2US 10,682,399 B2The University of Birmingham · 2020